研究疾病:
|
免疫性血小板减少症
|
研究疾病代码:
|
|
Target disease:
|
Immune thrombocytopenia
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
探索性研究/预试验
Pilot clinical trial
|
研究目的:
|
临床上通过随机对照临床研究方法,验证益气通阳方治疗慢性免疫性血小板减少症有效性、安全性,明确其优势以及探索益气通阳方治疗慢性免疫性血小板减少症的作用机制。
|
Objectives of Study:
|
Objective to verify the efficacy and safety of Yiqi Tongyang recipe in the treatment of chronic immune thrombocytopenia, clarify its advantages and explore the mechanism of Yiqi Tongyang recipe in the treatment of chronic immune thrombocytopenia.
|
药物成份或治疗方案详述:
|
纳入60例符合纳入标准的患者。随机分为益气通阳方观察组30例,归脾汤对照组30例。同时纳入健康人10例作为健康对照组进行机制研究。 实验组予益气通阳方治疗。组成:太子参、桂枝、麸炒白术、茯苓、炙甘草、白芍、锁阳、淫羊藿、巴戟天。对照组予归脾汤治疗。组成:党参、炙黄芪、麸炒白术、当归、茯苓、远志、龙眼肉、木香、炙甘草。两组药味临床均可随症加减。病人自行砂锅煎制,日一剂,早晚分服。
|
Description for medicine or protocol of treatment in detail:
|
We will include 60 patients who meet the inclusion criteria. Then they are randomly divided into Yiqi Tongyang Decoction observation group (30 cases) and Guipi Decoction control group (30 cases). At the same time, 10 healthy people are included as healthy control group for mechanism study. The experimental group is treated with Yiqi Tongyang decoction. Composition: Radix Pseudostellariae, Ramulus Cinnamomi, Rhizoma Atractylodis Macrocephalae, Poria cocos, Radix Glycyrrhizae, Radix Paeoniae Alba, Cynomorium songaricum, Herba Epimedii, Morinda officinalis. The control group is treated with Guipi Decoction. Composition: Radix Codonopsis, Radix Astragali, Rhizoma Atractylodis Macrocephalae, angelica, Poria cocos, Radix Polygalae, longan meat, Radix Aucklandiae, Radix Glycyrrhizae. The taste of the two groups can be modified with the symptoms. Patients will be self - frying casserole, one dose a day, sooner or later.
|
纳入标准:
|
(1)明确诊断为ITP,病程>12个月,年龄18~75岁,80×10^9 /L >PLT>10×10^9 /L 或有出血症状;
(2)符合中医紫癜病脾肾阳虚证诊断;
(3)患者知情同意、自愿参加、坚持定时服药。
(4)知情同意、自愿参加、年龄18~60岁的体检健康人群。
|
Inclusion criteria
|
1. The patients with definite diagnosis of ITP, whose course of disease is more than 12 months, aged 18-75 years, 80 x 10^9 /L > PLT >10 x 10 ^ 9 / L or bleeding symptoms;
2. Patients with purpura of spleen and kidney yang deficiency syndrome of TCM;
3. Patients with informed consent, voluntary participation and regular medication.
4. Healthy people with informed consent, voluntary participation and age of 18-60.
|
排除标准:
|
(1)就诊前 3 月内经过大剂量糖皮质激素冲击治疗的患者;
(2)就诊前30天内接受除激素以外的其他治疗,或参加其它临床研究,对疗效观察指标可能有影响者。
(3)严重免疫缺陷或严重的消化道和(或)脏器出血的患者;
(4)严重心、肝、肾功能障碍:血肌酐大于正常值上限; 丙氨酸转氨酶、天冬氨酸酶、胆红素大于正常值的2倍;NYHA分级≥Ⅱ级;或精神疾病患者;
(5)妊娠、哺乳期妇女或过敏体质者。
|
Exclusion criteria:
|
1. Patients who received high-dose glucocorticoid pulse therapy within 3 months before treatment.
2. The subjects who received other treatments except hormone within 30 days before treatment, or participated in other clinical studies, which may have an impact on the observation indexes of curative effect.
3. Patients with severe immune deficiency or severe gastrointestinal and / or visceral bleeding.
4. Patients with severe heart, liver and kidney dysfunction: serum creatinine is higher than the upper limit of normal value; Alanine aminotransferase, aspartate aminotransferase and bilirubin were 2 times higher than normal; NYHA grade >= grade II; Or mental illness patients.
5. Pregnant, lactating women or subjects with allergic constitution.
|
研究实施时间:
Study execute time:
|
从From
2021-02-10
至To
2022-02-09
|
征募观察对象时间:
Recruiting time:
|
从From
2021-02-10
至To
2022-02-09
|